Sister Patricia Codey, SC, Esq., president of the Catholic HealthCare Partnership of New Jersey, discusses legislation in New Jersey that could change the way tiered health plans are created.
Sister Patricia Codey, SC, Esq., president of the Catholic HealthCare Partnership of New Jersey, discusses legislation in New Jersey that could change the way tiered health plans are created.
Transcript (slightly modified)
A Senate committee will discuss legislation that would change the way tiered health plans are created in New Jersey. What are the key parts of this legislation?
On Monday there’s going to be a hearing in the senate commerce committee in regards to a package of bills dealing with OMNIA. And I really applaud the leadership of Senator (Joseph) Vitale and Senator (Nia) Gill. … They certainly have taken up the challenge; they certainly have been working with various stakeholders to try to come up with some legislation that provides the following:
One would be transparency. Transparency is very, very important in the industry.
The second item is, what are the standards that would be used to evaluate how someone comes to be in a tiered network, and then what weight do we give those standards?
And is there an opportunity for all stakeholders to come to the table and make their cases?
I would applaud the efforts that are being made on the legislative front, certainly it’s a bipartisan effort, but we really need evaluate what happened and how we can move forward. And I believe this legislation will provide that.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More